Background We evaluated the safety and efficacy of etanercept, a soluble tumor necrosis
factor receptor (p75):Fc fusion protein, in children with polyarticular juvenile rheumatoid …

OBJECTIVE: To develop preliminary criteria for inactive disease and clinical remission for
select categories of juvenile idiopathic arthritis (JIA), and to decide what such clinical states …

Background Some children with juvenile idiopathic arthritis either do not respond, or are
intolerant to, treatment with disease-modifying antirheumatic drugs, including anti-tumour …

Objective To prospectively validate the preliminary criteria for clinical inactive disease (CID)
in patients with select categories of juvenile idiopathic arthritis (JIA). Methods We used the …

We used the Immunochip array to analyze 2,816 individuals with juvenile idiopathic arthritis
(JIA), comprising the most common subtypes (oligoarticular and rheumatoid factor–negative …

Objective To evaluate the safety and efficacy of up to 8 years of etanercept treatment in patients
with polyarticular‐course juvenile rheumatoid arthritis (JRA). Methods Patients with JRA …

Objective: To report the initial and long-term outcome after an intensive exercise therapy
program for childhood complex regional pain syndrome, type I (CRPS). Design: Prospective …

Objective. To revise the current juvenile idiopathic arthritis (JIA) International League of
Associations for Rheumatology (ILAR) classification criteria with an evidence-based approach, …

Objectives. To determine initial intravenous gammaglobulin (IVIG) treatment failures in Kawasaki
disease (KD) and to report the outcome of retreatment and our use of pulse intravenous …

Objective To determine whether aggressive treatment initiated early in the course of rheumatoid
factor (RF)–positive or RF‐negative polyarticular juvenile idiopathic arthritis (JIA) can …